Y. Padilla-González

IFN-α as Induction and Maintenance Treatment of Patients Newly Diagnosed with Waldenström's Macroglobulinemia

J. A. Aviña-Zubieta, J. Vela-Ojeda, M. Vadillo-Buenfil, 2002 .

Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor

A. Majluf-Cruz, H. Mayani, J. Vela-Ojeda, 2008, Annals of Hematology.

[CD200 protein, bad prognostic in patients with multiple myeloma].

J. Vela-Ojeda, M. G. Garcia-Ruiz Esparza, L. Montiel-Cervantes, 2015, Revista medica del Instituto Mexicano del Seguro Social.

Serum calcium is an independent prognostic factor of overall survival in Mexican patients with multiple myeloma.

L. Montiel-Cervantes, E. Sánchez-Cortés, M. Xolotl-Castillo, 2012, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan

J. Vela-Ojeda, G. Ruiz-Argüelles, D. Gómez-Almaguer, 2007, Annals of Hematology.

Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia

J. Vela-Ojeda, A. Rosas-Cabral, M. G. Garcia-Ruiz Esparza, 2002, Annals of Hematology.